Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution

“…Patient preference or starting the treatment regimen prior to our center being involved with the care occasionally led to deviation from these recommendations. The technique of implantation at our center has been previously described ( 10 ).…”

“…The major benefit of Cs-131 is the shorter duration of the bothersome voiding symptoms that accompany PB ( 7 −9 ). For this reason, our center began using this isotope exclusively in our PB program in 2006 ( 10 ). Results using Cs-131 have been excellent and similar across different institutions ( 11 −13 ).…”

ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer

“…65 Experience with cesium-131 is less established compared with the other two isotopes, but 5-year biochemical control rates are favorable, and a recently published phase II study demonstrated similar quality of life outcomes among patients treated with palladium-103, iodine-125, and cesium-131. 66,67…”

“…One randomized trial examined differences between the two isotopes (palladium-103 and iodine-125), which noted no significant differences in long-term morbidity or PSA-based cancer control 65. Experience with cesium-131 is less established compared with the other two isotopes, but 5-year biochemical control rates are favorable, and a recently published phase II study demonstrated similar quality of life outcomes among patients treated with palladium-103, iodine-125, and cesium-131 66,67…”